The FDA added it to injectable semaglutide in January 2025, and it climbs the dose axis like everything else. Burning or tingling skin tracks the dose, not the weight lost, and an active-comparator study put the risk about twice that of another weight-loss drug. The mechanism remains unsettled
Biweekly or Monthly Injections: For ongoing maintenance or prevention of deficiency
However, studies using beta-3-adrenergic receptor knockout mice revealed a more complex picture: Long-term AOD-9604 treatment failed to produce weight loss in beta-3-AR knockout mice Acute administration still increased energy expenditure and fat oxidation in knockout mice This suggests beta-3-AR expression enhancement contributes to, but does not directly mediate, lipolytic effects The peptide appears to work through an unidentified receptor mechanism that subsequently influences beta-3-adrenergic signaling pathways
The goal is sustainable improvement, not rapid or extreme weight loss, with benefits that include improved energy, focus, and metabolic stability
There are no restrictions for food or alcohol after Botox
Long-term human safety has not been fully established